Pacira Rejects Activist Claims, Highlights Performance Ahead of Shareholder Vote
PCRX sits 28% above its 52-week low of $18.8.
Summary
Pacira BioSciences issued a letter to stockholders, defending its strategic direction and board nominees against activist investor DOMA Perpetual Capital Management. This communication is a key part of the ongoing proxy battle, which has seen multiple filings and public statements from both sides since March. The company highlighted a 31% stock price increase since the launch of its "5x30 strategy" and reiterated strong 2025 financial results, including $7.0 million GAAP net income and $726.4 million in revenue. Pacira also detailed progress in product growth, such as a 6.2% increase in EXPAREL volume in 2025, and advancements in its clinical pipeline. The letter aims to secure shareholder votes for its nominees ahead of the annual meeting on June 9, 2026, which will decide the company's future leadership.
At the time of this announcement, PCRX was trading at $24.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $945.6M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.